GSK launches $50m venture capital fund
GlaxoSmithKline (GSK) has launched a $50m strategic venture capital fund, Action Potential Venture Capital (APVC), to make investments in the biotech and bioelectric medicines industries.
More on Venture
Redalpine expands leadership team amid CHF 1bn-plus fundraise
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
VC Profile: RTP Global gears up to deploy largest fund to date, remains bullish on breakout opportunities
Partner Gareth Jefferies discusses early-stage deployment plans and advantages of supporting startups throughout their lifecycle
Medicxi raises USD 400m to invest in single-focus life sciences companies
GP's fourth fund will deploy USD 10m-USD 20m tickets in narrow indications of unmet need; backed by pharma
Women in PE: Earth Capital's Bezuidenhoudt and Hockley on 2024 fund launch progress and co-investment pipeline
UK-based impact investorтs female leaders discuss deployment plans and the advantages of its syndicate co-investment strategy
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds